Rick,
Prudential/Vector analyst Johm Sonnier did not help us today. He put a hold on GLIA stock based on the risk of decellerating Adcon sales and price runup. What run up? I do not know this guy but the analysis is less than impressive.
-------------
(snip)We are encouraged by the progress of the
therapeutic division, which we do not believe has received adequate
attention. This year, Gliatech should see an active news calendar, with
the completion of two pivotal trials for additional ADCON products and
Japanese approval of ADCON-L. However, as the stock has appreciated over
50% in the past 12 months, and as we believe the momentum of ADCON-L sales
could see some slow down, we believe the shares are fairly valued at
current levels. We expect fully taxed earnings in 1999, 2000, and 2001 of
$0.14, $0.48, and $0.61, respectively.(snip)
V1
|
